## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.0% below STRENGTH zone (4.0-10.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($141.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Jim Cramer on Agilent: “It Sure Feels Like This Company’s Finally Gotten Its Groove Back”**
- Source: Insider Monkey | 20251129T125300 | Bullish | Relevance: 99%
- Jim Cramer highlighted Agilent Technologies, Inc. (NYSE: A) as a company that has "gotten its groove back" after a strong quarterly performance. The company reported a modest top and bottom-line beat, with organic revenue up 7.2%, surpassing Wall Street's 5.3% expectation, and provided robust revenue guidance for 2026. Despite a slight dip from its COVID-year peak, Cramer noted the stock rallied over 2% following the earnings report.

**2. Quadrant Capital Group LLC Purchases 3,395 Shares of Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251201T110202 | Somewhat-Bullish | Relevance: 99%
- Quadrant Capital Group LLC increased its stake in Agilent Technologies by 40.2%, purchasing an additional 3,395 shares, bringing their total holdings to 11,846 shares valued at $1.398 million. The medical research company recently beat quarterly earnings estimates with $1.59 EPS and $1.86 billion in revenue, and has raised its quarterly dividend to $0.255. Insider activity shows CEO Padraig Mcdonnell sold 12,490 shares in November.

**3. Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight**
- Source: Business Wire | 20251201T132123 | Bullish | Relevance: 99%
- Agilent Technologies Inc. announced the release of new 21 CFR Part 11 compliance software for its xCELLigence RTCA eSight system. This software extends the system's applicability to GMP-regulated manufacturing and quality control settings, addressing the growing demand for compliant digital lab tools in biopharma and cell therapy. The upgrade features secure user authentication, electronic signatures, and complete audit trails, ensuring data integrity and streamlining regulatory submissions.

**4. Agilent Technologies (NYSE: A) CEO surrenders 1,948 shares for taxes**
- Source: Stock Titan | 20251201T163400 | Neutral | Relevance: 99%
- Agilent Technologies' President and CEO, Padraig McDonnell, surrendered 1,948 shares of common stock on November 26, 2025, to cover tax liabilities arising from the vesting of restricted stock units. This transaction, executed at $154.37 per share, is described as a routine administrative act to satisfy taxes, not an open-market sale. After this surrender, the CEO beneficially owns 66,539 shares of Agilent common stock.

**5. Agilent Technologies (A): Assessing Valuation Following Strong Q4 Results and Upbeat 2026 Guidance**
- Source: Sahm | 20251130T151600 | Bullish | Relevance: 99%
- Agilent Technologies (A) reported strong Q4 results and provided upbeat 2026 revenue guidance, leading to a surge in its share price. While one valuation narrative suggests the company is 8.4% undervalued with a fair value of $167.57, a Simply Wall St DCF model values it at $146.54, slightly below its current market price. The company benefits from increased global healthcare demand and expanding R&D budgets but faces risks from supply chain complexities and tightening research budgets.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |
| 2025-11-25 | UBS | $180 | $170 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |
| 2025-11-25 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 22.9x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $40.7B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 22.9 |
| Current P/E | 25.2 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.9% to -0.0% (-5.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.0pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.01% (CS: 50) | Neutral |
| RSI_14 | 55.2 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 1.214x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $150.10
- **Stop Loss:** $141.66 (5.6% risk)
- **Target:** $158.54 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 88
- **Position Value:** $13,208.80
- **Portfolio %:** 13.21%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*